/** blogpostTitle: Jubilant Ingrevia Q4 FY26: Volume-led quarter, CDMO milestones, and a sharper portfolio mix blogpostSlug: jubilant-fy26 blogpostCoverImageDescription: Ultra-realistic corporate finance scene inside a modern boardroom. A large wall-mounted dashboard shows three clean line charts and stacked bars representing quarterly revenue and EBITDA trend over 12 quarters and segment EBITDA share shift toward Specialty Chemicals and Nutrition. A separate panel shows a simple debt table trend with net debt declining year-on-year and a net debt to EBITDA ratio near 1.0x. The visuals use neutral colors, crisp lighting, and no logos or text labels. */

Jubilant Ingrevia Q4 FY26: Volume-led quarter, CDMO milestones, and a sharper portfolio mix

Jubilant Ingrevia closed Q4 FY26 with its highest quarterly revenue in 14 quarters, supported by volume growth and a steady improvement in profitability. Consolidated revenue from operations for Q4 FY26 stood at INR 1,179 crore, up 12 percent year-on-year. EBITDA rose 11 percent YoY to INR 172 crore, while profit after tax after exceptional items increased 17 percent YoY to INR 86 crore.

Management positioned the quarter as a test of operational resilience. Amid disruptions linked to the Middle East crisis, the company stated there was no force majeure and zero production loss, supported by diversified sourcing and pass-through mechanisms with customers.

The quarter also marked two strategic milestones that the company believes strengthen the medium-term growth trajectory. First, dispatches began from the newly constructed agro CDMO facility, with the first shipment to a global agro innovator dispatched in March 2026. Second, Jubilant Ingrevia completed the acquisition of Remidex Pharma to expand its presence in human nutrition and premix solutions.

A quarter where volumes did the heavy lifting

Management attributed the Q4 FY26 improvement largely to volume growth, with some pricing tailwinds emerging in the second half of the quarter due to higher crude-linked costs and pass-through. The company stated Q4 FY26 was driven by 10 percent volume growth.

Profitability improved sequentially, with EBITDA up 26 percent QoQ and PAT up 84 percent QoQ. The company also noted that PAT was impacted by INR 13 crore due to amendments under the Indian labour code.

Below is a compact snapshot of headline financials from the presentation.

Segment performance: Specialty drives profits, Nutrition recovers, Intermediates stabilize in Q4

Specialty Chemicals continued to anchor profitability. In Q4 FY26, the segment delivered revenue of INR 516 crore and EBITDA of INR 139 crore, with margin around 27 percent. On a full-year basis, FY26 segment revenue was INR 1,937 crore and EBITDA was INR 510 crore.

Management said Specialty benefited from volume momentum in Pyridine and derivatives, steady growth in fine chemicals and diketene derivatives, and improved contribution from CDMO, including the start of a large agro contract. Pricing was described as muted during parts of the quarter due to pressure from China, with some improvement toward the end.

Nutrition and Health Solutions showed a clear quarter-on-quarter recovery. Q4 FY26 revenue grew 21 percent YoY to INR 230 crore, while EBITDA improved 42 percent QoQ to INR 32 crore. Management highlighted Niacinamide as the key growth driver, supported by cosmetics demand, and pointed to improving choline volumes with export traction in Europe.

Chemical Intermediates posted improved quarterly performance, with Q4 FY26 revenue of INR 433 crore and EBITDA of INR 22 crore. Management attributed the improvement to better realizations supported by cost pass-through and higher volumes. However, full-year profitability remained weak versus the prior year: FY26 segment EBITDA fell to INR 73 crore from INR 108 crore in FY25.

A quick segment comparison based on the reported segment numbers is below.

Strategy and execution: Pinnacle, pipeline, and investments behind growth

The company continues to frame its strategy through the Pinnacle journey, launched around two years ago. Management stated early outcomes are visible in a stronger portfolio mix, improved customer relationships, and a more efficient cost structure.

One of the central execution metrics cited was the opportunity funnel. The company stated it has 100 plus opportunities with an estimated INR 3,400 crore potential, including 20 plus confirmed molecules with around INR 1,500 crore peak revenue, and an additional pipeline of 10 plus advanced stage molecules with around INR 1,100 crore peak revenue.

The presentation also points to operational initiatives. Management cited lean savings of INR 120 plus crore in FY26 and a 97th percentile ranking in the S and P Global Corporate Sustainability Assessment. The company also highlighted recognitions and audits, including WEF Lighthouse recognition and a USFDA audit of the Bharuch site with zero observations.

On the capital allocation side, the company indicated continued investment in growth capacity. Capex cash outflow in Q4 FY26 was INR 69 crore, primarily for commissioning of the Bharuch CDMO plant and ground-breaking of the Gajraula multi-purpose plant.

In the earnings call, the CFO guided FY27 capex in the range of INR 400 to 500 crore, and stated the Gajraula MPP is expected to be finished in FY27 and commence production in Q4 FY27.

FY27 outlook: sequential growth ambition with key moving parts

Management provided a clear qualitative view for FY27. Growth is expected to be led by Specialty Chemicals and Nutrition, along with recovery in acetyls. Management also stated it expects sequential growth in revenue and EBITDA starting Q1 FY27.

On the earnings call, management articulated an aspiration of at least 20 percent year-on-year growth in EBITDA on a full-year basis. The company did not provide quarterly guidance, citing potential lumpiness due to shipment timing and contract movements.

Two operational variables will be closely watched in FY27.

First, the large agro CDMO contract. Management confirmed commercial shipments started in March 2026 and stated the contract forms a main pillar of growth projections. At the same time, it noted that volume visibility beyond the near term depends on customer scenarios, though it also said the contract includes commitments intended to protect the company if volumes are delayed.

Second, the acetyls cycle. Management acknowledged that acetic acid prices had seen sharp moves due to the war-linked disruption and said it has been thoughtful about inventory and expects any inventory impact to be managed within Q1 or early Q2.

Closing takeaways

Q4 FY26 reinforced Jubilant Ingrevia’s improving operating momentum, with volume-led growth, stable consolidated margins, and a continued shift in EBITDA contribution toward Specialty Chemicals and Nutrition. The company also used the quarter to underline execution capability, from managing supply disruption without production loss to commissioning a new agro CDMO facility and integrating an acquisition to deepen its human nutrition offering.

FY27 is framed by management as a pivotal year. The company is pairing a target of sustained EBITDA growth with continued capex in CDMO capacity, while keeping a close eye on cyclicality in chemical intermediates. The biggest determinant of narrative credibility will be how quickly CDMO scale-up and the pipeline of molecules translate into consistent revenue and EBITDA progression over the next few quarters.